Sangamo posts Q2 net loss $0.18/sh, cash $27.8M; signs Genentech deal for up to $1.9B

SANGAMO THERAPEUTICS, INC

2024-Q2 EPS reported -$0.44 revenue$837,000

Signed global license with Genentech for zinc finger repressors targeting tau and STAC-BBB capsid; $50M near-term, up to $1.9B milestones plus royalties.
Q2 net loss $36.1M ($0.18/sh) vs $114.5M ($0.66); revenue $0.3M down from $6.8M.
Cash $27.8M at June 30; with Genentech $50M, runway into Q1 2025.
Pfizer's Phase 3 hemophilia A gene therapy met primary endpoint; Sangamo eligible for up to $220M milestones and 14-20% royalties.
Fabry disease: 33 patients dosed, 17 off ERT; eGFR improvement observed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.